REFERENCES
- Reeves SW, Sloan FA, Lee PP, et al. Uveitis in the elderly: Epidemiological data from the National Long-Term Care Survey Medicare Cohort. Ophthalmology. 2006;113:307.
- Shen DF, Chang MA, Matteson DM, et al. Biphasic ocular inflammatory response to endotoxin-induced uveitis in the mouse. Arch Ophthalmol. 2000;118:521–527.
- Moreland LW. Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1998;24:579–591.
- Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141–147.
- Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2005;44:1008–1011.
- Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56:3248–3252.
- Kaipiainen-Seppanen O, Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumor necrosis factor alpha inhibitors. Ann Rheum Dis. 2003;62:88–89.
- Cobo-Ibanez T, Del Carmen OM, Munoz-Fernandez S, et al. (2008). Do TNF-blockers reduce or induce uveitis? Oxford: Rheumatology. 47:731–741.
- Reeves SW, Sloan FA, Lee PP, et al. Uveitis in the elderly: Epidemiological data from the National Long-Term Care Survey Medicare Cohort. Ophthalmology. 2006;113:307.
- Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
- Okada AA, Sakai J, Usui M, et al. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm. 1998;6:111–120.
- Fleisher LN, Ferrell JB, McGahan MC. Ocular inflammatory effects of intravitreally injected tumor necrosis factor-alpha and endotoxin. Inflammation. 1990;14:325–335.
- Rosenbaum JT, Howes EL Jr, Rubin RM, et al. Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. Am J Pathol. 1988;133:47–53.
- Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121:437–440.
- Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45:252–257.
- Perez-Guijo V, Santos-Lacomba M, Sanchez-Hernandez M, et al. Tumor necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: The involvement of HLA-B27. Curr Med Res Opin. 2004;20:155–157.
- Kasner L, Chan CC, Whitcup SM, et al. The paradoxical effect of tumor necrosis factor alpha (TNF-alpha) in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 1993;34:2911–2917.
- Okamoto S, Streilein JW. Role of inflammatory cytokines in induction of anterior chamber-associated immune deviation. Ocul Immunol Inflamm. 1998;6:1–11.
- Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18–23.
- Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye (Lond). 2009;23:1868–1870.
- Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California: The Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111:491–500.
- Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol. 2003;87:925.
- Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. J Dermatolog Treat. 2009;20:100–108.
- Yazisiz V, Avci AB, Erbasan F, et al. Development of Crohn’s disease following anti-tumor necrosis factor therapy (etanercept). Colorectal Dis. 2008;10:953–954.
- Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411–452.
- Li X, Qin J. Modulation of Toll-interleukin 1 receptor mediated signaling. J Mol Med. 2005;83:258–266.
- Ranganathan P. Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics. 2005;6:481–490.
- El-Shabrawi Y, Wegscheider BJ, Weger M, et al. Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27-associated uveitis: Association with susceptibility and clinical manifestations. Ophthalmology. 2006;113:695–700.